Full Press Release Details
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
PVLA Neutral Sentiment
Schlehuber, S., & Skerra, A. (2002) Tuning ligand affinity, specificity, and folding stability of an engineered lipocalin variant – a so-called ‘anticalin’ – using a molecular random approach. Biophys. Chem. 96, 213-228.
Key Takeaway: The article discusses a study by Schlehuber and Skerra on tuning ligand affinity, specificity, and folding stability of an engineered lipocalin variant known as 'anticalin'. The research is published in Biophysical Chemistry. The text appears to be a placeholder with no additional details provided.
Price reaction · baseline $22.05 (2025-06-20 close) · 21 other PVLA headline(s) in the window, move may be shared
day 0 close · peak
+2.2%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+106%
120-day peak, hindsight
Typical move
8.9%
average across 5 past catalysts
Cash runway
~58 mo
Minimal dilution risk
Lead asset
PTX-022
Phase 3 · Pachyonychia Congenita